Sentiment · ABT

Lobbying Spend for ABT

AI-generated plain-English read of lobbying spend for ABT. Updated daily.

Lobbying intensity is easing from a heavy base. Prior policy battles are likely resolved or de-prioritized. Neutral on its own — lean on fundamentals.

What will probably happen

Easing spend typically means prior policy battles are resolved or de-prioritized. Neutral from a risk standpoint; investigate whether the issue resolved favorably.
Spend is spread across many issue areas — the company has diverse regulatory exposure and is fighting on multiple fronts simultaneously.

What to do

If you HOLD this stock: Lobbying intensity is easing — prior policy battles likely resolved or de-prioritized. Neutral read; hold and lean on fundamentals.
If you're EVALUATING this stock: No regulatory red flag from this channel right now. Lean on fundamentals for sizing.
If you trade OPTIONS: Lobbying pulling back from heavy base = lower regulatory binary risk. If IV is elevated on regulatory fear, selling premium may be defensible.

10 quarters of history with $15.80M in total spend — sufficient data for a reliable trajectory read.

Technical details

Technical analysis

Spend tier: Heavy
Trajectory: Declining
Last quarter: $1.70M
Last 4Q total: $6.23M
Prior 4Q total: $7.17M
Top issue area: HEALTH ISSUES (38% of spend)
Top registrant: ABBOTT LABORATORIES (79% of spend)
Registrant base: In house
Quarters on record: 10
Unique issue areas: 14
Unique registrants: 13
Issue concentration: Broad

Key levels

Key price and metric levels
Level	Value
total amount	15,802,496
last 4q total	6,230,000
top issue pct	0.381
prior 4q total	7,172,496
top registrant pct	0.794
last quarter amount	1,700,000

Caveats

Lobbying disclosures are quarterly and reflect activity already past. The signal is structural, not timing.
The primary registrant appears to be an in-house government-affairs operation. In-house lobbying may not be captured in full by third-party disclosure data.